FDA has rejected Summit Therapeutics and Akeso’s ivonescimab in a narrow-stage lung cancer setting, according to the reported decision. Analysts had expected a negative outcome, but the company class—anti-TROP2/EGFR?—remains a focus for investors assessing the durability of targeted antibody development pathways. The rejection adds a regulatory setback to an area where developers are competing to show survival or response benefit in biomarker-defined subpopulations. The decision also underscores the bar for demonstrable clinical value in tightly specified indications. For biotech teams, the outcome highlights how single-arm signals and endpoint choice can become decisive in FDA reviews, particularly when the eligible population is small and prior therapy lines shape baseline risk. The near-term impact is likely to be concentrated on ivonescimab’s development plan and any ongoing confirmatory strategy tied to the rejected indication.